Vaccinex Shares Are Trading Lower. The Company Provided an Update on New Clinical Findings From Its SIGNAL-AD Phase 1b/2 Trial of Pepinemab Antibody in Alzheimer's Disease.

Benzinga12:45 ET

Vaccinex Shares Resume Trade

BenzingaOct 31 10:22 ET

Vaccinex Shares Halted On Circuit Breaker To The Upside, Stock Now Up 6.20%

BenzingaOct 31 10:02 ET

Vaccinex Stock Spikes On 'Promising' Data On Alzheimer's Drug Study: Retail Sentiment Brightens

BarchartOct 25 07:18 ET

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference on October 31, 2024

GlobeNewswireOct 24 08:30 ET

Express News | Vaccinex to Report Promising New Efficacy Data for Signal-Ad Phase 1B/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (Ctad) Conference on October 31, 2024

ReutersOct 24 08:30 ET